Chair: Kanu Chatterjee

10:00 AM
Welcome and Introduction
Kanu Chatterjee

10:05 AM
Atrial Fibrillation in Heart Failure: Rate, Rhythm and Current Management
Albert L. Waldo

10:30 AM
Revascularization in Heart Failure: Imaging and Patient Selection
Anthony DeMaria

10:55 AM
Anemia Complicating Heart Failure: Pathophysiology and Clinical Trials
Christopher M. O'Connor

11:20 AM
Left Ventricular Assist Devices: Update on Current Status
James Chen-Tson Fang

11:45 AM
Panel Discussion, Questions and Answers

11:55 AM
Closing Remarks
Kanu Chatterjee

Supported by an educational grant from Amgen, Inc.

This satellite program is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

Chair: Scott D. Solomon

10:00 AM
Welcome and Introduction
Scott D. Solomon

10:05 AM
Epidemiology of Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction
Dalane W. Kitzman

10:25 AM
Pathophysiology of Diastolic Dysfunction and Preserved Ejection Fraction Heart Failure
Michael R. Zile

10:45 AM
Diagnostic Approaches to Diastolic Dysfunction
Invited

11:05 AM
Potential Therapeutic Approaches in Patients with Diastolic Dysfunction or Preserved Systolic Function Heart Failure
Scott D. Solomon

11:30 AM
Moderated Questions & Answers
Invited

11:55 AM
Closing Remarks

Supported by an educational grant from Novartis Pharmaceuticals.

This satellite program is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

Chair: John R. Teerlink

10:00 AM
Welcome and Program Overview
John R. Teerlink

10:05 AM
Case Study: Acute Heart Failure Syndrome Patient Followed Through Continuum of Treatment in the US
John R. Teerlink

10:15 AM
Treatment Approaches in the US
Kirkwood F. Adams, Jr.

10:25 AM
Case Study: Acute Heart Failure Syndrome Patient Followed Through Continuum of Treatment in Europe
Alexandre Mebazaa

10:35 AM
Treatment Approaches in Europe
Markku Nieminen

10:45 AM
Clinical Trial History of Current Acute Heart Failure Treatments and Identification and Challenges of Unmet Needs
Mihai Gheorghiade

11:00 AM
Future Strategies in Acute Heart Failure Management and Clinical Trial Design: Interactive Panel Discussion
Faculty

Supported by an educational grant from Abbott Laboratories.

This satellite program is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

Moderators: Thomas Force
                   Yibin Wang

1:00 PM^*
Novel Akt-regulated Paracrine Cardiac Effectors
Victor J. Dzau

1:30 PM^*
GDF-15 as a Novel Cardioprotective Factor
Jeffery Molkentin

2:00 PM^*
CNN1 as a Novel Cardiac Effector Protein
Helmut Drexler

2:30 PM^*
p8 and Gene 33: Novel Mediators of Hypertrophy, Matrix Remodeling, and Cell Death
John M. Kyriakis

3:00 PM^*
CDK-9 Mediated Regulation of Growth and Death
Michael D. Schneider

^*25 minutes presentation, 5 minute audience discussion.

Chair: James B. Young

1:00 PM
Introduction and Overview of Acute Decompensated Heart Failure (ADHF)
James B. Young

1:10 PM
Case in Point: The Hypertensive ADHF Patient
W. Frank Peacock

1:30 PM
Case in Point: The Normotensive ADHF Patient
James B. Young

1:50 PM
Questions & Answers

2:00 PM
Case in Point: The Hypotensive ADHF Patient
Kirkwood F. Adams, Jr.

2:20 PM
Case in Point: ADHF Patients and Surgical Intervention
John M. Luber

2:40 PM
Questions & Answers

2:50 PM
Closing Comments & Evaluations

Supported by an educational grant from Scios, Inc.

This satellite program is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

Chair: Milton Packer

1:00 PM
Welcome and Introduction
Milton Packer

1:05 PM
The Burden of Heart Failure: Recent Insights into Epidemiology of and Clinical Outcomes in Heart Failure
Lynne Warner Stevenson

1:30 PM
Positive Inotropes in the Management of Heart Failure: A Review of the Evidence
Barry M. Massie

1:55 PM
Cardiac Sarcomere: Basic Unit of Myocardial Contractility and a Therapeutic Target in Heart Failure
R. John Solaro

2:20 PM
Cardiac Myosin Activation: A Novel Approach to Treatment of Heart Failure
John R. Teerlink

2:45 PM
Panel Discussion/Questions & Answers

2:55 PM
Closing Remarks
Milton Packer

Supported by an educational grant from Cytokinetics.

This satellite program is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

Chair: Kanu Chatterjee

4:00 PM
Welcome and Introduction
Kanu Chatterjee

4:05 PM
Pathophysiology of Acute Decompensated Heart Failure and Therapeutic Options
Kanu Chatterjee

4:30 PM
Contemporary Fluid Management Options for Congestive Heart Failure
Peter E. Carson

4:55 PM
What Have We Learned and Where Are We Heading: Emerging Therapies in Heart Failure
Marvin A. Konstam

5:20 PM
Defining the Place of Vasopressin Receptor Antagonists in the Treatment of Decompensated Heart Failure
JoAnn Lindenfeld

5:45 PM
Panel Discussion, Questions & Answers
Kanu Chatterjee

Supported by an educational grant from Otsuka America Pharmaceutical, Inc.

This satellite program is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

Chair: James B. Young

4:00 PM
Welcome and Introduction
James B. Young

4:05 PM
Case #1: Elderly Male with Hypertension and Metabolic Syndrome at High risk for HF (Stage A): What Should Be First-Line Therapy?

     Perspective #1 Contemporary use of      Beta- Blockers
     Gregg C. Fonarow

     Perspective #2 Date for ACEIs and ARBs:      Mixing the Old with the New
     Barry H. Greenberg

4:35 PM
Case #2: Female with Systolic dysfunction Post-MI, LBBB and No Symptoms of HF (Stage B): It's All About the EF

     Perspective #1 The Relevance of      Neurohormonal Antagonism in Post-MI LVD
     Mariell Jessup

     Perspective #2 Sorting Out the Issues of      ICD/CRT
     Gregg C. Fonarow

5:05 PM
Case #3: African American Hypertensive Diabetic Female with Concentric LVH and Marked Sympotms of HF (Stage C): When Risk Becomes a Reality

     Perspective #1 Managing Special      Populations in HF with and Without      Preserved
     Barry H. Greenberg

     Perspective #2 The Importance of      In-Hospital Initiation of Evidence-Based      Therapies
     Nancy M. Albert

5:35 PM
Question and Answer Session

Supported by an educational grant from GlaxoSmithKline USA.

This satellite program is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

Chair: Marc A. Silver

4:00 PM
Welcome and Opening Remarks
Marc A. Silver

4:05 PM
Fluid Status and Activity: Ongoing Assessment and the Impact On Patient Management in Heart Failure
Marc A. Silver

4:25 PM
Remote Monitoring in Disease Management of Heart Failure: What Does the Research Say?
Andrew L. Smith

4:45 PM
Utility of Remote Monitoring in the Management of Arrhythmias: The EP Specialist’s Perspective
Leonard I. Ganz

5:05 PM
New Advances in Heart Failure Diagnostics in Remote Monitoring: Benefit Through Collaborative Care
Roberta Bogaev

5:25 PM
Management of Heart Failure: A Multidisciplinary Approach
Roberta Bogaev, MD
Rebecca L. Angerstein, RN

5:35 PM
Panel Discussion

Supported by an educational grant from Guidant Foundation.

This satellite program is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

Chair: Stuart D. Russell

4:00 PM
Introduction and Welcome
Stuart D. Russell

4:05 PM
Outcomes with Current Medical Therapies
Wayne C. Levy

4:25 PM
Current Outcomes with LVADs: Are Some Patients Too Sick?
Leslie W. Miller

4:45 PM
Is Destination Therapy a Reasonable Therapy: Update on New Devices
Francis D. Pagani

5:05 PM
Partnering with Local Medical Centers for Destination Therapy
Stephanie A. Moore

5:25 PM
Advanced Heart Failure: When to Refer
Stuart D. Russell 5:45 PM
Questions and Answers

Supported by an educational grant from Thoratec Corporation.

This satellite program is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

Chair: Jagmeet P. Singh

7:00 AM
Welcome and Introductions
Jagmeet P. Singh

7:05 AM
The Evolving Role of Implantable Devices: The Shape of Things to Come
Paul Wang

7:25 AM
The CRT Patient: A Multidisciplinary Approach to Optimal Care
Marc J. Semigran

7:45 AM
Questions and Answers
Faculty

Supported by an educational grant from St. Jude Medical, Inc.

This satellite program is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

Chair: Douglas L. Mann

7:00 AM
Introduction
Douglas L. Mann

7:05 AM
Challenges in Designing Clinical Trials for Devices: An Investigator's Perspective
Douglas L. Mann

7:20 AM
How Do We Choose Patients for Device Therapy (CRT, LVAD, and Cardiac Support Devices)?
Randall C. Starling

7:35 AM
Future Directions of Device Therapy: The Cardiac Surgeon's Perspective
Steven F. Bolling

7:50 AM
Questions and Answers

Supported by an educational grant from Acorn Cardiovascular, Inc.

This satellite program is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

Chair: Alan S. Maisel

7:00 AM
Welcome and Introductions
Alan S. Maisel

7:05 AM
Emerging Role of B-Type Natriuretic Peptide in Assessing and Treating Patients with Cardiovascular Disease
Alan S. Maisel

7:15 AM
Clinical Value of Measuring B-Type Natriuretic Peptide Levels
Invited

7:30 AM
Therapeutic Applications of B-Type Natriuretic Peptide in Heart Failure
Clyde W. Yancy

7:50 AM
Panel Discussion

Supported by an educational grant from Scios, Inc. and Biosite Diagnostics, Inc.

This satellite program is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

Moderators: Jay N. Cohn
                  Arthur M. Feldman

8:30 AM
President's Address
Gary S. Francis

8:45 AM
The Promise of Universal Health Care
Kevin Grumbach

9:10 AM
The Private Sector is the Answer
Robert E. Moffitt

9:35 AM
The Problems of Achieving Universal Health Care
Invited

Moderators: JoAnn Lindenfeld
                   J. Herbert Patterson

10:30 AM
Introduction
Kirkwood F. Adams

10:35 AM
Management of Acute Decompensation
JoAnn Lindenfeld

10:55 AM
Pharmacologic Therapy in Chronic HF
Jonathan G. Howlett

11:15 AM
Device Management
Mandeep R. Mehra

11:35 AM
Panel Discussion

Moderators: Anita Deswal
                   Javed Butler

10:30 AM
Metabolic Syndrome: Prevalance and Relevance to Heart Failure
Allison M. Prichett

10:50 AM
The Metabolic Syndrome: Does It Have a Role to Play in Clinical or Public Health Practice
Michael P. Stern

11:10 AM
Myocardial Insulin Resistance: Mechanisms and Clinical Implications
Richard P. Shannon

11:30 AM
Are TZDs and Biguanides Safe in HF?
W.H. Wilson Tang

11:50 AM
Panel Discussion

Moderators: Sandra B. Dunbar
                   Susan J. Pressler

10:30 AM^*
Changes in Depression, Anxiety, and Social Support in Heart Failure Outpatients With Implantable Cardioverter Defibrillators
Sue A. Thomas

10:48 AM^*
Heart Failure Caregivers: An Assessment of Burden and Concern
Mary Beth Barry

11:06 AM^*
6-Minute Walk's Correlation with Subjective Measures of Functional Capacity in Black Patients with Chronic Heart Failure
Meriam F. Caboral

11:24 AM^*
Thoracic Impedance Measured via Implantable Devices Provides Advanced Warning Signs and Symptoms of Worsening Heart Failure in Addition to Hospitalization
Lisa D. Rathman

11:42 AM^*
Socio-Demographic and Clinical Predictors for Rehospitalization in Heart Failure
Jill H. Esquivel

^* 10 minute abstract presentation, 8 minute discussion

Moderators: Blase A. Carabello
                   Peter P. Liu

10:30 AM^*
The Heart-Kidney Connection: Myocardial Infarction Accelerates Glomerular Dysfunction, Hypertrophy and Proteinuria in the Presence of Experimental Mild Renal Insufficiency
Fernando L. Martin

10:48 AM^*
Favorable Renal Hemodynamic Effects of Intra-Renal Nesiritide Infusion in Heart Transplant Patients
Andrew T. Ho

11:06 AM^*
Long-Term Apelin Infusion Rescues Chronic Cardiomyopathy and Potentiates the Effects of ACE-Inhibition
Ramachandra R. Sista

11:24 AM^*
Diastolic Function in Patients with Heart Failure and Preserved Ejection Fraction: A Population Based Study
Carolyn S.P. Lam

11:42 AM^*
Risk Score to Predict Survival to Hospital Discharge After Left-Ventricular Assist Device (LVAD) Implantation as Destination Therapy (DT)
Katherine Lietz

^* 15 minute presentation followed by 3 minutes discussion

Supported by an educational grant from Novartis Pharmaceuticals.

Moderators: Kenneth B. Margulies
                  Douglas B. Sawyer

10:30 AM^*
On Obligatory Role for Sox17 in Cardiac Myocyte Formation by ES Cells
Yu Liu

10:48 AM^*
Apelin Regulates Cardiac Contractility and Rescues Neurohormonal Heart Failure
Kavita V. Ernst

11:06 AM^*
Long-Term Expression of Human Growth Hormones by rAAV Protects Cardiac Myocytes After Myocardial Infarction in Rats
Ryuichi Aikawa

11:24 AM^*
SCF/C-KIT Compensates for FL/FLT3 Deficiency to Mediate Myocardial Rescue and Repair Post-MI
Bilal B. Ayach

11:42 AM^*
Regulatory Mechanisms of Ectodomain Cleavage of Angiotensin-Converting Enzyme2
Michikado Iwata

^* 10 minute presentation followed by 8 minutes discussion

Supported by an educational grant from Novartis Pharmaceuticals.

Chair: William H. Gaasch

12:30 PM
Introduction
William H. Gaasch


12:35 PM
Overview of Diastolic Heart Failure and Current Management Issues
William C. Little


12:50 PM
Current Status of Implantable Hemodynamic Monitoring Technology
Philip B. Adamson


1:05 PM
Modern Management of Patients with Diastolic Heart Failure
Michael R. Zile


1:20 PM
Questions and Answers

Supported by an educational grant from Medtronic, Inc.

This satellite program is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

1. How Does a Research Coordinator Prepare For An FDA Audit
   Invited, Bill G. White, Laura M. Yamakoski



2. Managing the Patient With a Ventricular Assist Device
   Reynolds M. Delgado, Michelle L. Edwards, Leslie W. Miller



3. How to Manage Right Heart Failure
   Donald Chomsky, Curt J. Daniels, Evelyn Horn



4. How to Use Beta Blockers in Patients With Potential Contraindications
   Nancy Albert, Mark E. Dunlap, Patricia A. Uber



5. How to Set Up a Home Exercise Program For HF Patients
   Vera A. Bittner, Jennifer L. Dekerlegand, Rebecca A. Gary

Moderator: Marc J. Semigran

12:30 PM
Overview
Marc J. Semigran

12:40 PM^*
Prevalence of Microchimerism in Women in Dilated Cardiomyopathy
Linda Cadaret (016)

12:50 PM^*
Chronic Heart Rate of 90 Leads to Clinical Deterioration and Lower Ejection Fraction in Patients with Heart Failure
Krishnamurti Rao (017)

1:00 PM^*
Differential Biological Actions and Assay Detection of Altered Forms of BNP in Vitro
Denise M. Heublein (092)

1:10 PM^*
GRK2 Expression in Lymphocytes of Human Patients with Heart Failure: A New Biomarker
Amit Mittal (2005-06 HFSA Research Fellow) (130)

1:20 PM^*
Sildenafil Therapy for Systolic Heart Failure with Secondary Pulmonary Hypertension: A Randomized Double-Blind, Placebo-Controlled Study
Gregory D. Lewis (2005-06 HFSA Research Fellow) (223)

^* 5 minute presentation, 5 minutes discussion

Moderators: Rebecca B. Costello
                   Lorraine S. Evangelista

2:00 PM
Pathophysiology of Nutrition-Induced Cardiomyopathy
Robert J. Gropler

2:20 PM
What Have We Learned From Spontaneous Animal Models
Lisa Freeman

2:40 PM
Macro- and Micronutrients in HF Patients
Laura D. Carbone

3:00 PM
Current Recommendations for Nutritional Therapy in HF
Abby G. Ershow

3:20 PM
Panel Discussion

Moderators: Edward P. Havranek
                  Paul J. Hauptman

2:00 PM
The Burgeoning Health Care Costs in the USA
Invited

2:20 PM
Heart Failure: What Does It Cost?
Paul A. Heidenreich

2:40 PM
Devices: Controlling the Cost
Gillian Sanders

3:00 PM
Is Disease Management Cost Effective?
Gregory L. Freeman

3:20 PM
Panel Discussion

Moderators: Peter E. Carson
                   David S. Feldman

2:00 PM
Endothelial Cell Function
Thomas F. Luscher

2:20 PM
Peripheral Circulatory Abnormalities: Cause or Effect?
Thierry H. LeJemtel

2:40 PM
Role of Oxidative Stress in Vascular Dysfunction
Helmut Drexler

3:00 PM
Where Coronary Atherosclerosis Comes From and How We Might Make it Quickly Go Away
Kevin Williams

3:20 PM
Panel Discussion

Moderators: William G. Stevenson
                   John P. Boehmer

2:00 PM
Magnitude of the Problem
Bruce L. Wilkoff

2:20 PM
Why Does Resynchronization Fail: Can We Predict Failure to Respond?
David B. DeLurgio

2:40 PM
What Do We Do With Nonresponders: Assessing Lead Replacement and Device Programming in the Nonresponder
Michael O. Sweeney

3:00 PM
Can Echo Help to Minimize Nonresponders?
John Gottdiener

3:20 PM
Panel Discussion

Moderators: Roger J. Hajjar
                   Steven R. Houser

2:00 PM
Repairing Damaged Myocardium Using Gene Therapy
Walter J. Koch

2:20 PM
Regenerating the Coronary Vasculature After MI
Jay M. Edelberg

2:40 PM
Regenerating Myocytes After MI: Roles of Akt and IGF
Mark A. Sussman

3:00 PM
Engineering New Myocardial Tissue
Wolfram H. Zimmermann

3:20 PM
Panel Discussion

Judge: Marvin A. Konstam

4:00 PM - Opening Remarks
Judge Marvin A. Konstam Presiding

4:10 PM - Opening Statements
(10 minutes each)

Prosecuting Team Leader: Barry H. Greenberg

Defense Team Leader: Marc A. Pfeffer

4:30 PM - Arguments For/Against (Team Leader and Witnesses)
(10 minutes each for arguments, 5 minutes for questions to witnesses)

Prosecuting Team Witnesses: Mandeep R. Mehra, Gregory C. Fonarow

Defense Team Witnesses: David L. DeMets, John R. Teerlink

5:00 PM - Rebuttal
(7.5 minutes each)

Prosecuting Team Leader
Defense Team Leader

5:15 PM - Final Comments
(10 minutes)
Presiding Judge

5:25 PM - Jury Decision (Audience)

Moderators: Paul A. Heidenreich
                   Barbara J. Riegel

4:00 PM
Defining and Conceptualizing Quality of Life: What's Being Measured?
Thomas R. Rector

4:20 PM
Has The Reliability and Validity of Quality of Life Instruments Been Established?
John A. Spertus

4:40 PM
Is QOL Measuring Disease Severity or Physchological Well Being?
Willem J. Kop

5:00 PM
Insights Into Collecting QOL Data: Are We Capturing the Patients' Values?
Kathleen A. Dracup

5:20 PM
Panel Discussion

Moderators: Marrick L. Kukin
                   Hector O. Ventura

4:00 PM
Pathophysiologic Mechanisms Linking Sleep Apnea and Heart Failure
Virend K. Somers

4:20 PM
Screening for Sleep Disordered Breathing in Heart Failure
Steven Scharf

4:40 PM
Treatment of OSA in Heart Failure
Barbara A. Phillips

5:00 PM
Treatment of CSA in Heart Failure
David P. White

5:20 PM
Panel Discussion

Moderators: Daniel Burkhoff
                     Steven B. Houser

4:00 PM
Foxglove and Beyond: A Historical Perspective on Ca Coupling and Heart Failure
Arnold M. Katz

4:20 PM
CAM Kinase Mediated Alterations in EC Coupling in Heart Failure
Donald M. Bers

4:40 PM
CAM Kinase and Cardiac Arrhythmias in CHF
Mark E. Anderson

5:00 PM
New Clinical Approaches to Improve EC Coupling and Block Arrhythmias
Xander Wehrens

5:20 PM
Panel Discussion

Chair: William T. Abraham

7:00 AM
Welcome and Introductions
William T. Abraham

7:05 AM
Sleep Apnea in Heart Failure
Shahrokh Javaheri

7:20 AM
Sleep Apnea in Patients with Heart Failure: Practical Considerations in Diagnosis and Treatment
Rami N. Khayat

7:35 AM
Integrating Heart Failure and Sleep Medicine Programs to Optimize Care
William T. Abraham

7:50 AM
Questions and Answers

Supported by an educational grant from Respironics, Inc.

This satellite program is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

Chair: Maria Rosa Costanzo

7:00 AM
Welcome and Introductions
Maria Rosa Costanzo

7:05 AM
Volume Overload: Diagnostic Dilemmas and Prognostic Implications
Mariell Jessup

7:20 AM
Diuretics: The Good, the Bad, the Ugly
J. Thomas Heywood

7:35 AM
Mechanical Fluid Removal: Insights From the UNLOAD Trial
Maria Rosa Costanzo

7:50 AM
Panel Discussion

Supported by an educational grant from CHF Solutions.

This satellite program is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

Chair: Barry M. Massie

7:00 AM
Welcome and Introduction
Barry M. Massie

7:05 AM
Venous Thromboembolism in Heart Failure
John B. O'Connell

7:25 AM
Arterial Thromboembolism in Heart Failure
Barry M. Massie

7:45 AM
Panel Discussion/Questions and Answers
Faculty

7:55 AM
Closing Remarks
Barry M. Massie

Supported by an educational grant from sanofi-aventis.

This satellite program is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

Moderators: Uri Elkayam
                   Mary Ann Lukas

8:30 AM
Introduction
Uri Elkayam

Global Studies in Heart Failure: What Are the Limitations?

8:35 AM
Investigator Point of View
Marc A. Pfeffer

8:40 AM
Industry Point of View
Invited

How to Design a Perfect Global Study in Heart Failure

8:45 AM
The Investigator Perspective (North America)
Robert M. Califf

8:55 AM
The Investigator Perspective (Europe)
John G.F. Cleland

9:05 AM
The Industry Perspective
Cesare Orlandi

9:15 AM
The Regulatory Perspective (FDA)
Norman L. Stockbridge

9:25 AM
The Regulatory Perspective (EMEA)
Invited

9:35 AM
Panel Discussion

Moderators: Gary S. Francis
                   Kenneth Dickstein

8:30 AM
Polymorphisms and Hap-Maps
Michael R. Bristow

8:47 AM
End-of-Life Planning: The European Model
Christopher Ward

What are the Appropriate Clinical Trial End-Points for Patients with Acute Decompensated Heart Failure:

9:04 AM
The US Perspective
Raymond Lipicky

9:21 AM
The European Perspective
Jose Lopez-Sendon

9:38 AM
Panel Discussion

Moderators: Alan B. Miller
                   Stuart D. Russel

8:30 AM
Mechanisms of Atrial Fibrillation
Jeffery Olgin

8:50 AM
Does Pharmacologic Management of Atrial Fibrillation Improve Heart Failure Patients: Rate Control vs. Rhythm Control
Denis Roy

9:10 AM
The Evolving Role of Ablation
Andrea Natale

9:30 AM
Autonomic Nerve Activity and Atrial Fibrillation in HF
Peng-Sheng Chen

9:50 AM
Panel Discussion

Moderators: Howard J. Eisen
                   Daniel Levy

8:30 AM
Screening: What is the Role?
Thomas Jue-Fuu Wang

8:50 AM
The Importance of Hypertension
Donald M. Lloyd-Jones

9:10 AM
The Challenges of Life Style Modification
Anita Deswal

9:30 AM
How to Prevent Cardiomyopathy After Cancer Treatment
Jean-Bernard Durand

9:50 AM
Panel Discussion

Moderators: Mathew S. Maurer
                   William C. Little

8:30 AM
LV Structure and Function and the Development of Diastolic Heart Failure
William H. Gaasch

8:50 AM
Myofilament/Extramyofilament Structures: Which Changes Contribute to Contractile Dysfunction?
R. John Solaro

9:10 AM
Extracellular Matrix-Induced Changes in Ventricular and Vascular Structure and Function
Francisco J. Villareal

9:30 AM
Current and Future Therapies: Application of Advances in Basic Science to Clinical Care of Diastolic Heart Failure
Michael R. Zile

9:50 AM
Panel Discussion

Moderators: Mariell L. Jessup

Panelists:
JoAnn Lindenfeld
Katherine J. Hoercher
Erika D. Feller
Monica R. Shah
J. Malcolm O. Arnold

Moderators: Satish Kenchaiah
                   Heather Ross

10:30 AM
Outstanding Issues: What Do We Still Need to Prove?
Michael W. Rich

10:50 AM
Role of Remote Monitoring in HF
Alfred A. Bove

11:10 AM
What Do We Really Know About Educating Patients
Debra K. Moser

11:30 AM
Focus on the Family
Kay Blum

11:50 AM
Panel Discussion

Moderators: Alan S. Maisel
                   Jonathan Sackerner-Bernstein

10:30 AM
ProBNP, BNP and Altered Circulating Forms: An Overview
John C. Burnett

10:50 AM
Current BNP/NT-proBNP Assays: What Do They Target and What Other Things Might They Recognize
Margaret M. Redfield

11:10 AM
Utility of BNP and the Management of Patients
Milton Packer

11:30 AM
The Limitations of Current BNP and NT Pro-BNP Assays
Stephen S. Gottlieb

11:50 AM
Panel Discussion

Moderators: William S. Colucci
                   Peter P. Liu

10:30 AM
Cardiac Innate Immunity: An Overview
Douglas L. Mann

10:50 AM
TWEAK as a Target
Ronglih Liao

11:10 AM
Statins as Immunomodulatory Agents
Henry Krum

11:30 AM
Is There A Role for Immunadsorption
Leslie T. Cooper

11:50 AM
Panel Discussion

Moderators: Thomas K. Borg
                   Michael R. Bristow

10:30 AM
Molecular Basis For Cardiac Fibrosis
Barry H. Greenberg

10:50 AM
Modifying Matrix Degradation in Hypertrophy and Failure
Francis G. Spinale

11:10 AM
Cellular Mechanisms That Contribute to Myocardial Fibrosis
Mark L. Entman

11:30 AM
Novel Pathways That Inhibit Myocardial Fibrosis
Howard B. Haimes

11:50 AM
Panel Discussion

Chair: Gregg C. Fonoraw

12:30 PM
Welcome and Introductions
Gregg C. Fonoraw

12:35 PM
Guidelines-Recommended Medication and Device Therapy For Heart Failure in 2006
Clyde W. Yancy

12:50 PM
Proactive Monitoring and Management of Heart Failure: Role of New Technology
William T. Abraham

1:05 PM
Improving the Quality of Heart Failure Care
Gregg C. Fonoraw

1:20 PM
Questions and Answers
Faculty

Supported by an educational grant from Medtronic, Inc.

This satellite program is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

6. How to Manage Acute Decompensated HF in the ED
   D. Michael Felker, W. Franklin Peacock, Kumudha Ramasubbu



7. Research Coordinators: How to Manage Principal Investigators Who Don't Do Their Job in a Clinical Trial
   Jalal K. Ghali, Joanne P. Marshall, Susan Ziesche



8. How to Interpret Exercise Testing With Gas Exchange: Practical Use of Data and Predictive Value as a Diagnostic Test
   Gregory A. Ewald, Donna M. Mancini, Ileana L. Piña



9. How to Manage HF in Disadvantaged Populations
   Ginger Conway, Jo E. Rodgers, Sue Wingate



10. How to Manage Arthritic Pain
    Invited, Sara J. Goodlin, Sara C. Paul

Moderator: Wilson S. Colucci

12:30 PM
Overview
Wilson S. Colucci

12:40 PM
Effective Treatment Reduces Arterial Stiffness and Load in Decompensated Heart Failure
Sunil Matiwala (2005-06 HFSA Research Fellow) (056)

12:50 PM
Adoptive Transfer of Hypertension with CD4+ Lymphocytes
Katherine Horak (108)

12:56 PM
A Novel Mitochrondial Matrix Serine/Threonine Protein Phosphatase is Essential to Cardiomyocyte Survival and Cardiac Function by Regulating Mitochondrial Permeability Transition
Gang Lu (136)

1:10 PM
CXCR4 Improves Cardiac Remodeling and Neovascularization, and Regulated Inflammatory and Progenitor Stem Cell Mobilization Post-Myocardial Infarction
Bilal B. Ayach (141)

1:20 PM
Ventricular Remodeling in Infarcted Mouse Hearts Can be Controlled by Molecular Induction of Intracardiac Graft Cell Proliferation
Kelly R. Stevens (146)

Moderators: Arnold M. Katz
                   Carl V. Leier

2:00 PM^*
Translate from Percents into Patients Per 100
Lynne Warner Stevenson

2:18 PM^*
Poetry and Prayers: Volitional Rhythmic Breathing To Treat Heart Failure
Patricia A. Uber

2:36 PM^*
A Modest Proposal: ICDs For Everyone Except For Those with Heart Failure
Brian Olshansky

2:54 PM^*
Therapy that Improves Prognosis in Systolic Heart Failure Cannot be Expected to have Similar Benefits In Diastolic Heart Failure
Arnold M. Katz

3:12 PM^*
Texas No-Limit Hold’Em: Dealing with Patient Preferences and Uncertainty
Paul Hauptman

^* 10 minute presentations followed by 8 minutes audience discussion

Moderators: William T. Abraham
                   Guillermo Torre-Amione

2:00 PM
LVADs: Will Smaller Devices Work?
Michael A. Acker

2:20 PM
Percutaneous Support Devices
Biswajit Kar

2:40 PM
Passive Cardiac Support
Randall C. Starling

3:00 PM
Baroreflex and Vagus Nerve Stimulation
Hani N. Sabbah

3:20 PM
Panel Discussion

Moderators: Philip M. Barger
                   Thomas Force

2:00 PM
pFOX Inhibitors: Friend or Foe?
William C. Stanley

2:20 PM
Adiponectin and Cardiac Remodeling
Kenneth Walsh

2:40 PM
The AMPK/Malonyl-CoA Axis as a Therapeutic Target For the Ailing Heart
Gary D. Lopaschuk

3:00 PM
Nuclear Receptors as Targets for Metabolic Therapy
Janice M. Huss

3:20 PM
Panel Discussion

Moderators: Barry M. Massie
                   Milton Packer

DEBATE: Practive Guidelines Should Mandate the Management of Heart Failure Patients

4:00 PM
Protagonist: Marvin A. Konstam

4:15 PM
Antagonist: Jay N. Cohn

4:30 PM
Rebuttals/Summary (5 minutes each)

DEBATE: Which Drug Should Be Added After a Beta Blocker and ACE Inhibitor?

4:40 PM
Isosorbide Dinitrate and Hydralazine: Anne L. Taylor

4:53 PM
Aldosterone Antagonist: Bertrum Pitt

5:07 PM
ARBs: Christopher B. Granger

5:20 PM
Rebuttals/Summary (5 minutes each)

Moderators: Inder Anand
                   Sanjiv Kaul

4:00 PM
LV Structure and Function by CMR: Comparison to Other Modalities and Implications for Clinical Trials
Craig S. Broberg

4:20 PM
Assessing Viability and Non-Viability in LV Dysfunction
Gilford Raff

4:40 PM
Interrogating the Arrhythmic Substrate in Heart Failure by CMR
Katherine C. Wu

5:00 PM
Tracking Results of Regenerative Therapies
Joseph Wu

5:20 PM
Panel Discussion

Moderators: Meredith Bond
                   Edmund H. Sonnenblick

4:00 PM
Molecular Signaling in Pathological Hypertrophy: Are These Viable Targets?
Gerald W. Dorn, II

4:20 PM
Protein KinaseG Signaling in Cardiac Hypertrophy: Is Reverse Remodeling Achievable?
Michael E. Mendelsohn

4:40 PM
Adrenergic Signaling in Pathological Hypertrophy
Howard A. Rockman

5:00 PM
Novel Inhibitors of Pathologic Signaling in HF
Timothy McKinsey

5:20 PM
Panel Discussion

Moderators: James E. Udelson
                   Clyde W. Yancy

8:30 AM^*
Evaluation of the Safety and Efficacy of the OPTIMIZER II and III Systems with Active Fixation Leads in Subjects with HF Resulting from Systolic Dysfunction: FIX-CHF-4
Martin Borggrefe

8:45 AM^*
Aspirin and the Risk of Heart Failure Hospitalization in Patients with Atrial Fibrillation and a Prior History of Heart Failure: An ACTIVE-W Analysis
Akshay S. Desai

9:00 AM^*
Effects of the Adenosine A1 Receptor Antagonist KW-3902, Alone and in Combination with Furosemide, on Diuresis and Renal Function in Hospitalized Acute Decompensated HF Patients with Renal Impairment or Refractory to Maximum Dose of Conventional Diuretics: Randomized, Double-Blind, Placebo-Controlled Studies
Barry M. Massie

9:15 AM^*
The Selective Cardiac Myosin Activator CK-1827452, a Calcium-Independent Inotrope, Increases LV Systolic Function by Increasing Ejection Time: Results of a First-in-Human Study of a Unique and Novel Mechanism
John R. Teerlink

9:30 AM^*
The ACCLAIM Trial: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Immune Modulation Therapy in Patients with HF due to Systolic LV Dysfunction
Invited

9:45 AM^*
Efficacy and Safety Study of Oxypurinol Added to Standard Therapy in Patients with NYHA Class III-IV CHF (OPT-CHF)
Joshua Hare

^* 15 minutes allotted, 12 minute presentation, 3 minutes for audience discussion

Moderators: Michelle L. Edwards
                   Roberta C. Bogaev

8:30 AM
Biology of Aging
Edward G. Lakatta

8:50 AM
Problems in Pharmacotherapeutics and Adherence in Aging
Michael D. Murray

9:10 AM
Impact of Social, Psychological and Economic Problems on Heart Failure Management
Nancy Albert

9:30 AM
Quality of Life vs. Prolonging Life
Karin Kirchhoff

9:50 AM
Panel Discussion

Moderators: Mihai Gheorghiade
                   David N. Rosenthal

8:30 AM
Genetic Cardiomyopathies
Ray E. Hershberger

8:50 AM
Viral Cardiomyopathies
Heinz-Peter Schultheiss

9:10 AM
Cardiomyopathy in Children
Jeffrey A. Towbin

9:30 AM
Hypertrophic Cardiomyopathy
Robert Roberts

9:50 AM
Panel Discussion

Moderators: Horng H. Chen
                   Stuart D. Katz

8:30 AM
Phosphodiesterase 5 in the Heart
Hunter Champion

8:50 AM
Phosphodiesterase 5 in the Lung
Marc J. Semigran

9:10 AM
Phosphodiesterase 5 in the Kidney
Michael H. Humphreys

9:30 AM
Safety of PDE-5 Inhibitors in Patients With Heart Failure For Erectile Dysfunction
Christopher M. O'Connor

9:50 AM
Panel Discussion

Moderators: Mandeep R. Mehra
                   Bruce L. Wilkoff

10:30 AM
Who Should Get an ICD
Invited

10:50 AM
Perspectives on ICD Reliability
Mark D. Carslon

11:10 AM
Patient Perspectives on ICDs
Lynne Warner Stevenson

11:30 AM
Managing the Morbidity of ICD Therapy
Bruce L. Wilkoff

11:50 AM
Panel Discussion

Moderators: Sandra B. Dunbar
                   Sharon A. Hunt

10:30 AM
Pathophysiology of the Depressed Heart
Philip F. Binkley

10:50 AM
Prevelance of Depression in HF
Varda Konstam

11:10 AM
Screening for Depression
Sue Ann Thomas

11:30 AM
Treatment of Depression
Richard Kast

11:50 AM
Panel Discussion

Moderators: John C. Burnett, Jr.
                   Barry M. Massie

10:30 AM
Adenosine Antagonists
Michael M. Givertz

10:50 AM
Arginine Vasopression
Steven R. Goldsmith

11:10 AM
Ultrafiltration Devices
Margaret M. Redfield

11:30 AM
New Information on Diuretics
Mark C.P. Haigney

11:50 AM
Panel Discussion